Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rimegepant - Pfizer

Next Previous
Drug Profile

Rimegepant - Pfizer

Alternative Names: BHV-3000; BMS-927711; NURTEC ODT; Rimegepant orally disintegrating tablet - Pfizer; Rimegepant sulfate - Pfizer; Rimegepant Zydis® ODT - Pfizer; Rimegepant Zydis® oral fast-dissolve tablet - Pfizer; VYDURA; Vydura

Latest Information Update: 24 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Pfizer
  • Class 2 ring heterocyclic compounds; Amines; Analgesics; Anti-inflammatories; Antimigraines; Antipsoriatics; Carbamates; Cycloheptanes; Fluorobenzenes; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Phase II/III Rhinosinusitis; Temporomandibular joint dysfunction syndrome
  • Phase II Plaque psoriasis; Trigeminal neuralgia

Most Recent Events

  • 24 Nov 2025 Pfizer initiates a phase I bioequivalence trial (In volunteers) in the US (NCT07261371)
  • 05 Apr 2025 Efficacy and adverse events data from phase III trial in Migraine presented at the 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)
  • 05 Apr 2025 Efficacy and adverse events data from phase III trial in Migraine presented at the 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top